10x Genomics Q2 revenue rises on Atera demand
TXG•Outlook
- 10x Genomics raises 2026 revenue guidance to $610 mln-$630 mln, from $600 mln-$625 mln.
- Company expects 2026 revenue growth of 2%-5% over 2025, excluding settlement revenue.
Result drivers
- Atera demand - Co cited strong early order flow and customer engagement for its Atera product as a key driver in the quarter, per CEO Serge Saxonov.
- Gross margin improvement - Co said higher gross margin was due to lower manufacturing costs, including $2.6 mln in tariff refunds, and reduced inventory write-downs.
- Settlement impact - Higher operating expenses were mainly due to a lower gain on settlement versus the prior year; underlying operating expenses were flat yr/yr.
Quarterly overview
- US life science tools firm's Q2 revenue rose 3% yr/yr, beating analyst expectations.
- Company posted a Q2 net loss as operating expenses rose on lower settlement gains.
- 10x Genomics raised full-year revenue guidance and completed the Proteintech Genomics acquisition.
Key details and analyst coverage
| Metric |
|---|
